BMS Opdivo trial scores early goal
January 14, 2015Research and Development, Sales and Marketing BMS, Merck, cancer nsclc, keytruda, nivolumab, opdivo
A late-stage trial of Bristol-Myers Squibb’s lung cancer drug Opdivo has been stopped early after showing promising results – but …
Immunocore names chief executive
January 14, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eliot Forster, immunocore
Oxford-based biotec Immunocore has announced the appointment of Dr Eliot Forster as its chief executive with immediate effect. Forster takes …
Lilly, BMS and Merck unite for cancer trials
January 13, 2015Research and Development, Sales and Marketing BMS, Cancer, Galunisertib, Merck, NSCLC, keytruda, lilly, oncology, opdivo
Lilly will test some of its compounds in combination with rival cancer drugs from Bristol-Myers Squibb and Merck, the companies …
Roche teams up to tackle antibiotics resistance
January 13, 2015Research and Development, Sales and Marketing Antibiotics, Fedora, Meiji, OP0595, Roche, Teixobactin
Roche is to collaborate with Japan-based pharma firm Meiji and Canadian Fedora – two companies specialising in the production of …
New UCB chief starts and expands team
January 13, 2015Sales and Marketing Cimzia, Jean-Christophe Tellier, Neupro, UCB, roch deliveux, vimpat
New UCB chief executive Jean-Christophe Tellier who succeeded Roch Doliveux this year has also welcomed three new members to the …
AMRI buys two Aptuit facilities
January 13, 2015Manufacturing and Production AMRI, Aptuit, cedarburg, glasgow, oso
Contract research and manufacturing firm AMRI has acquired two businesses from pharmaceutical services company Aptuit in a $60 million deal. …
Oryzon Genomics names CFO and executive VP
January 13, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gregory Weaver, Oryzon genomics
Spanish clinical stage biopharma firm Oryzon Genomics has appointed Gregory Weaver as its executive vice president and chief financial officer. …
Another NICE no for Dendreon cancer drug
January 13, 2015Sales and Marketing Cancer, Dendreon, FDA, NHS, NICE, Provenge, sipuleucel-T
Dendreon has seen its prostate cancer treatment for people whose disease has spread and who are not yet suitable for …
NHS drops 25 treatments from Cancer Drugs Fund
January 12, 2015Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus
Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …
AstraZeneca drops CDF application
January 12, 2015Sales and Marketing AstraZeneca, CDF, Cancer, NHS, NICE, lynparza, olaparib
AstraZeneca has withdrawn its application for its drug Lynparza to be on the Cancer Drugs Fund (CDF), citing concerns with …
Novartis enters digital tech collaboration
January 12, 2015Sales and Marketing Novartis, clinical trials, digital, mhealth, qualcomm, ventures
Novartis has entered an agreement with the US investment company Qualcomm Ventures to create a joint firm to support the …
Shire buys rare-disease firm NPS Pharma
January 12, 2015Sales and Marketing AbbVie, Shire, gattex, natpara, nps, nps pharma
Shire is to acquire rare diseases firm NPS Pharma to enhance its profile following the collapse of its deal with …
Roche stakes $1 billion in cancer gene research firm
January 12, 2015Research and Development, Sales and Marketing Cancer, Foundation Medicine, Genentech, Roche, genomics, jp morgan
Roche has announced a huge billion-dollar investment in the cancer genomics research firm Foundation Medicine. Timed with the beginning of …
Daiichi-Sankyo pays $39m to settle allegations
January 12, 2015Sales and Marketing Azor, Benicar, Daiichi Sankyo, Daiichi-Sankyo, Tribenzor, Welchol, kickbacks, us justice
Daiichi-Sankyo will pay the US government and state Medicaid programmes $39 million to resolve claims that it violated the False …
FDA approvals: 1996 versus 2014
January 12, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, John LaMattina, LaMattina, NDA, US, appovals, drugs
As highlighted in a number of recent stories, 2014 was a banner year for the biopharmaceutical industry with 41 new …
Heptares Therapeutics hires former GSK heads
January 12, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Atul Pande, GSK, Heptares, Roberto Solari
UK and US-based clinical-stage drug firm Heptares Therapeutics has appointed Atul Pande and Roberto Solari to its board of directors. …
Daiichi-Sankyo blood drug gets FDA nod
January 12, 2015Sales and Marketing BMS, Daiichi Sankyo, Daiichi-Sankyo, FDA, Pfizer, Pradaxa, atrial fibrillation, blood, savaysa
The US Food and Drug Administration has shown Daiichi-Sankyo’s anti-clotting drug Savaysa the green light to reduce the risk of …
Mixed results for Biogen’s MS drug
January 9, 2015Sales and Marketing Anti-LINGO-1, BIIB033, Biogen IDEC, MS, multiple sclerosis, plegridy
An experimental drug from Biogen Idec for the treatment of multiple sclerosis (MS) has shown a mixed bag of results …
Takeda trials Teva Parkinson’s drug in Japan
January 9, 2015Sales and Marketing Azilect, CHMP, Copaxone, Parkinson's, Takeda, rasagiline
Takeda has begun late stage trials for Teva’s Parkinson’s disease drug Azilect in Japan, with the hopes of bringing the …
Sanofi and Regeneron post positive alirocumab results
January 9, 2015Sales and Marketing Regeneron, Sanofi, cholesterol, heart, statin, statins
The latest trials of the potentially blockbuster new heart drug alirocumab show it lowers cholesterol in people at moderate and …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
